Synergistic effects of piperlongumine and gemcitabine against KRAS mutant lung cancer

To determine the combined efficacy of piperlongumine and gemcitabine for treatment of KRAS mutant lung cancer.The cell growth inhibition of piperlongumine, gemcitabine, and piperlongumine plus gemcitabine was measured by Cell Counting Kit‑8 assay and the combination index was calculated. In addition, the combined effects of piperlongumine and gemcitabine on cell apoptosis, reactive oxygen species (ROS) contents, and microtubule-associated...